Amgen (AMGN) › Analysis

Amgen (AMGN) stock analysis, November 3, 2026: Uptrend intact, but earnings land just below the high

Published November 3, 2026 · AMGN chart, levels and live analysis

Amgen (AMGN) goes into its third-quarter earnings report today at $461.86, less than 1% below its October 30 closing high of $466.01. The shares have gained 14.6% in a month while the S&P 500 fell. The balance of evidence leans positive for the next 2–6 weeks, with high conviction: the daily and weekly trends agree, and the stock leads both the market and healthcare. The catch is that a breakout from here offers 1.8 to 1 at best.

Why it matters

Amgen is scheduled to report today, as Investing.com noted in its Tuesday earnings preview. The results were not yet out as of this writing, so the stock's reaction is still ahead. What is visible is how much is already in the price. AMGN is up 41.1% year to date against 10.5% for SPY, and 40.0% over six months. Peers have given the sector a friendly backdrop: Yahoo Finance reports that J&J, Merck and Sanofi have already beaten estimates. A good quarter is the expectation, not a surprise.

Over the past five days AMGN rose 3.1%, XLV rose 2.8% and SPY fell 2.1%. The stock beat its sector by only 0.3 points, so this was mostly a healthcare move in a falling market, not a stock-specific one. The news does not explain why healthcare was bid. Today's 0.8% dip comes with no company headline behind it, and a Bloomberg feature on Amgen's obesity effort is background rather than new data.

The argument about AMGN is growth against durability. The bulls point to steady execution. The Motley Fool cites second-quarter revenue up 10% to $10.1 billion, with 22 products growing at double digits. Seeking Alpha notes the stock is up 18.4% since September 16, when it traded near $376. The cautious side is the same Motley Fool piece's warning that patent cliffs for Otezla and Enbrel loom. A separate Motley Fool comparison with Novo Nordisk flags a debt-to-equity ratio of 6.3 times. The obesity candidate MariTide, which Bloomberg frames as Amgen's route into a $120 billion market, is the piece of the story that is still unproven.

Valuation is where the Street and the tape disagree. Of 29 analysts, the consensus is hold, with a mean price target of $397.32. The shares trade 16.2% above that, and the targets range from $225 to $500. Even the most optimistic analyst sits only about 8% above the current price. The market has moved well ahead of the average analyst model.

What the evidence says

The long-term thesis is intact. Price is above its 40-week average, well above the 50-day average at $420.85 and the 200-day at $376.12. It is 55.9% above its 52-week low of $296.30 and within 1% of the high. The stock is in an advanced, extended phase of an uptrend: the trend is healthy, but much of the easy gain has been made.

For the next 2–6 weeks the balance of evidence leans positive, with high conviction, 3 of 4 points. The daily trend runs with the weekly uptrend. AMGN leads the S&P 500 over 50 days by 11.7 points and XLV by 2.9 points, so the strength is not just a sector tide. Over 200 days the lead on the S&P is 18.8 points.

The strongest case against is stretch. RSI is 72.5, a level that often brings pauses. Volume is running 65% below its 20-day average, though today's session is not finished. Earnings arrive with the stock at the highs, and the consensus price target is well below the price. These are reasons conviction is three points rather than four. They do not tip the balance because none of them breaks the trend or the relative strength, and a stock can stay overbought while a strong trend continues.

Levels that matter

The structure holds above $450, a round number with a swing zone at $446.43 just beneath it. A move under $450 would be the first crack. The trend ends below $420.85, the 50-day average, with $425 just above it as another round-number marker. Between $450 and $420.85 the stock could pull back a good deal without damaging the weekly uptrend.

The breakout level is a daily close above $466.01, the 52-week high, on volume above its 20-day average. From there the math uses a stop at $447.23, which is $450 less a quarter of the 14-day ATR of $11.10. The first target is $475, which gives 0.5 to 1. The second is $500, which gives 1.8 to 1. The math does not reach the 3 to 1 that makes a breakout worth the risk. That would take a target beyond $500, and no resistance level beyond it is on the map, or an entry closer to the stop after a pullback toward $450.

What would change the picture

A weekly close below $420.85, the 50-day average, would change the picture. It would mean the stock had given back most of the last month's gain and broken the trend that has run since September. The non-price fact that could do it is a cut to full-year guidance in the earnings release, which would undercut the 10% growth story and the valuation that has been built on it.

What to watch

Get a message when the AMGN picture changes — the agent team watches the levels and the news for you.Create a free account

More AMGN analyses

Research & education, not advice. MarketCrew is AI-powered and can make mistakes.